|
1. Taubes G. Cardiovascular disease: Does inflammation cut to the heart of the matter? Science 2002, 296: 242-245. 2. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.
3. Kushner I, Gewurz H, Benson M. C-reactive protein and the acute phase response. J Lab Clin Med 97 1981; 739-749. 4. MacIntyre SS, Schultz D, Kushner I. Biosynthesis of C-reactive protein. Ann N Y Acad Sci 1982; 389: 76-87. 5. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of Pneumococcus. J Exp Med 1930; 52: 561-571. 6. MacLeod CM, Avery OT. The occurrence during acute infections of a protein not normally present in the blood. J Exp Med 1941; 73:191-200. 7. Parish WE. Studies on vasculitis. Clin Allergy 1976; 6: 543-550. 8. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci 1982; 389: 406-417. 9. Li JJ, Sanders RL, McAdam KPWJ, Hales CA, et al. Impact of C-reactive protein (CRP) on surfactant function. J Trauma 1989; 29:1690-1697. 10. Kew RR, Hyers TM, Webster RO. Human C-reactive protein inhibits neutrophil chemotaxis in vitro: Possible implications for the adult respiratory distress syndrome. J Lab Clin Med 1990; 115: 339-345. 11. Malik AB, Horgan MJ. Mechanisms of thrombin-induced lung vascular injury and edema. Am Rev Respir Dis 1987; 136: 467-470. 12. Zouki C, Beauchamp M, Baron C, Filep JG. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest 1997; 100: 522-529. 13. Shields MJ, A hypothesis resolving the apparently disparate activities of native and altered forms of human C-reactive protein. Immunol Res 1993; 12: 37-47. 14. Diehl EE, Haines GK, Radosevich JA, Potempa LA. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 2000; 319: 79-83. 15. Ji SR, Wu Y, Potempa LA, Qiu Q, ZhaoJ. Interactions of C-reactive protein with low-density lipoproteins: Iimplications for an active role of modified C-reactive protein in atherosclerosis. Int J Biochem Cell Biol 2006; 38: 648-661. 16. Ji SR, Wu Y, Potempa LA, Liang YH, Zhao J. Effect of modified C-reactive protein on complement activation: A possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2006; 26: 935-941. 17. Yavin EJ, Fridkin M. Peptides derived from human C-reactive protein inhibit the enzymatic activities of human leukocyte elastase and cathepsin G: Use of overlapping peptide sequences to identify a unique inhibitor. J Pept Res 1998; 51: 282-289. 18. Heuertz RM, Ahmed N, Webster RO. Peptides derived from C-reactive protein inhibit neutrophil alveolitis. J Immunol 1996; 156: 3412-3417. 19. Ahmed N, Thorley R, Xia D, Samols D, Webster RO. Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. Am J Respir Crit Care Med 1996; 153: 1141-1147. 20. Ballou SP, Kushner I. C-reactive protein and the acute phase response. Adv Intern Med 1992; 37: 313-336. 21. Kushner I. C-reactive protein and the acute-phase response. Hosp Pract 1990; 25: 13, 16, 21-13, 16, 28. 22. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979. 23. Kushner I, Broder ML, Karp D. Control of the acute phase response. J Clin Invest 1978; 61: 235-242. 24. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the Monitoring Trends and Determinants in Cardiovascular Disease Augsburg Cohort (MONICA) Study, 1984 to 1992. Circulation 1999; 99: 237-242. 25. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-2011. 26. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospctive study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733. 27. Ridker PM, Bassuk SS, Toth PP. C-reactive protein and risk of cardiovascular disease: Evidence and clinical application. Curr Atheroscler Rep 2003; 5: 341-349. 28. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, Polak JF, Tracy RP. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: The cardiovascular health study. Circulation 2005; 112: 25-31. 29. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28. 30. Suk HJ, Ridker PM, Cook NR, Zee RY. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis 2005; 178:139-145. 31. Smith GD, Timpson N, Lawlor DA. C-reactive protein and cardiovascular disease risk: Still an unknown quantity? Ann Intern Med 2006; 145: 70-72. 32. Hage FG, Szalai AJ. C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007; 50: 1115-1122. 33. Lange LA, Carlson CS, Hindorff LA, Lange EM, Walston J, Durda JP, Cushman M, Bis JC, Zeng D, Lin D, Kuller LH, Nickerson DA, Psaty BM, Tracy RP, Reiner AP. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 2006; 296: 2703-2711. 34. Paik JK, Kim OY, Koh SJ, Jang Y, Chae JS, Kim JY, Kim HY, Hyun YJ, Cho JR, Lee JH. Additive effect of interleukin-6 and C-reactive protein (CRP) single nucleotide polymorphism on serum CRP concentration and other cardiovascular risk factors. Clin Chim Acta 2007; 380: 68-74. 35. Marz W, Scharnagl H, Hoffmann MM, Boehm BO, Winkelmann BR. The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Eur Heart J 2004; 25: 2109-2119. 36. Zhang L, Kao WH, Berthier-Schaad Y, Plantinga L, Fink N, Smith MW, Coresh J. C-Reactive protein haplotype predicts serum C-reactive protein levels but not cardiovascular disease risk in a dialysis cohort. Am J Kidney Dis 2007; 49: 118-126. 37. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 2006; 145: 35-42. 38. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: Clinical importance. Curr Probl Cardiol 2004; 29: 439-493. 39. Schlager O, Exner M, Mlekusch W, Sabeti S, Amighi J, Dick P, Wagner O, Koppensteiner R, Minar E, Schillinger M. C-reactive protein predicts future cardiovascular events in patients with carotid stenosis. Stroke 2007; 38: 1263-1268. 40. Fredrikson GN, Hedblad B, Nilsson JA, Alm R, Berglund G, Nilsson J. Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels. Metabolism 2004; 53: 1436-1442. 41. Fritsma G, High sensitivity C-reactive protein. Clin Lab Sci 2001; 14: 276-278. 42. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 1999; 19: 972-978. 43. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. Thromb Haemost 2006; 95: 511-518. 44. Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Dietary patterns and markers of systemic inflammation among Iranian women. J Nutr 2007; 137: 992-998. 45. Lopez-Garcia E, Schulze MB, Fung TT, Meigs JB, Rifai N, Manson JE, Hu FB. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 2004; 80: 1029-1035. 46. Schulze MB, Hoffmann K, Manson JE, Willett WC, Meigs JB, Weikert J, Heidemann C, Colditz GA, Hu FB. Dietary pattern, inflammation, and incidence of type 2 diabetes in women. Am J Clin Nutr 2005; 82: 675-684. 47. Humenikova L, Gates G. Relation between C-reactive protein and serum and dietary antioxidants in older adults at increased risk for cardiovascular disease. J Nutr Elder 2005; 24: 23-37. 48. Esposito K, Marfella R, Ciotola M, Di PC, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: A randomized trial. JAMA 2004; 292: 1440-1446. 9. Michalsen A, Lehmann N, Pithan C, Knoblauch NT, Moebus S, Kannenberg F., Binder L, Budde T., Dobos GJ. Mediterranean diet has no effect on markers of inflammation and metabolic risk factors in patients with coronary artery disease. Eur J Clin Nutr 2006; 60: 478-485. 50. Kaur G, Rao LV, Agrawal A, Pendurthi UR. Effect of wine phenolics on cytokine-induced C-reactive protein expression. J Thromb Haemost 2007; 5: 1309-1317. 51. Garcia-Lorda P, Bullo M, Balanza R, Salas-Salvado J. C-reactive protein, adiposity and cardiovascular risk factors in a Mediterranean population. Int J Obes (Lond) 2006; 30: 468-474. 52. Ohsawa M, Okayama A, Nakamura M, Onoda T, Kato K, Itai K, Yoshida Y, Ogawa A, Kawamura K, Hiramori K. CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-term smoking cessation in male smokers. Prev Med 2005; 41: 651-656. 53. Lawlor DA, Smith GD, Rumley A, Lowe GD, Ebrahim S. Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors. Thromb Haemost 2005; 93: 955-963. 54. Ryu SY, Lee YS, Park J, Kang MG, and Kim KS. Relations of plasma high-sensitivity C-reactive protein to various cardiovascular risk factors. J Korean Med Sci 2005; 20: 379-383. 55. Moghbeli N, Kirtane AJ, Ray KK, Murphy SA, Gibson CM, Braunwald E., Cannon CP. C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome. Am J Cardiol 2005; 96: 635-638. 56. Raitakari M, Mansikkaniemi K, Marniemi J, Viikari JS, Raitakari OT. Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults: The Cardiovascular Risk in Young Finns Study. J Intern Med 2005; 258: 428-434. 57. O'Callaghan PA, Fitzgerald A, Fogarty J, Gaffney P, Hanbidge M, Boran G, Enright H, Murphy J, McCarthy B, Graham IM. New and old cardiovascular risk factors: C-reactive protein, homocysteine, cysteine and von Willebrand factor increase risk, especially in smokers. Eur J Cardiovasc Prev Rehabil 2005;12: 542-547. 58. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005; 28: 690-693. 59. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397. 60. Bowden DW, Lange LA, Langefeld CD, Brosnihan KB, Freedman BI, Carr JJ, Wagenknecht LE, Herrington DM. The relationship between C-reactive protein and subclinical cardiovascular disease in the Diabetes Heart Study (DHS). Am Heart J 2005; 150: 1032-1038. 61. Zdrojewski T, Chwojnicki K, Bandosz P, Konarski R, Wyrzykowski B. Distribution of C-reactive protein and its relation to arterial hypertension in a country representing a high-risk region for cardiovascular diseases. Blood Press 2006; 15: 20-26. 62. Kraus VB, Stabler TV, Luta G, Renner JB, Dragomir AD, Jordan JM. Interpretation of serum C-reactive protein (CRP) levels for cardiovascular disease risk is complicated by race, pulmonary disease, body mass index, gender, and osteoarthritis. Osteoarthritis Cartilage 2007; 15: 966-971. 63. Nazmi A, Victora CG. Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health 2007; 7: 212. 64. Arena R, Arrowood JA, Fei DY, Helm S, Kraft KA. The relationship between C-reactive protein and other cardiovascular risk factors in men and women. J Cardiopulm Rehabil 2006; 26: 323-327. 65. Vitale C, Gebara O, Mercuro G, Wajngarten M, Silvestri A, Rossini P, Ramires JA, Fini M, Rosano GM. Value of C-reactive protein levels and IL-6 in predicting events levels in women at increased cardiovascular risk. Maturitas 2005; 50: 239-246. 66. Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 2005; 142: 425-432. 67. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291: 585-590. 68. Heikkila K, Ebrahim S, and D. A. Lawlor, A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 61, 824-833 (2007). 69. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q. Human C-reactive protein binds activating Fc gamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 2007; 12: 252-265. 70. Thombre PS, Deodhar SD. Inhibition of liver metastases in murine colon adenocarcinoma by liposomes contaiing human C-reactive protein or crude lymphokine. Cancer Immunol Immunother 1984; 16: 145-150. 71. Barna BP, Eppstein DA, Thomassen MJ, Nestor JJ, Ho T, Medendorp SV, Deodhar SD. Therapeutic effects of a synthetic peptide of C-reactive protein in pre-clinical tumor models. Cancer Immunol Immunother 1993; 36: 171-176. 72. Suarez EC. C-reactive protein is associated with psychological risk factors of cardiovascular disease in apparently healthy adults. Psychosom Med 2004; 66: 684-691. 73. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin A, Jenvey MC, Kolstoe SE, Thompson D, Wood SP. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-1221. 74. Heuertz RM, Piquette CA, Webster RO. Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis. Am J Pathol 1993; 142: 319-328. 75. Heuertz RM, Xia D, Samols D, Webster RO. Inhibition of C5a des arg-induced neutrophil alveolitis in transgenic mice expressing C-reactive protein. Am J Physiol 1994; 266: L649-L654. 76. Szalai AJ, Briles DE, Volanakis JE. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol 1995;155: 2557-2563. 77. Szalai AJ, Nataf S, Hu XZ, Barnum SR. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 2002;168: 5792-5797. 78. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397. 79. Szalai AJ, VanCott JL, McGhee JR, Volanakis JE, Benjamin WH. Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect Immun 2000; 68: 5652-5656. 80. Sepulveda JL, Mehta JL. C-reactive protein and cardiovascular disease: A critical appraisal. Curr Opin Cardiol 2005; 20: 407-416.
|